Quarterly report pursuant to Section 13 or 15(d)

Contingencies and commitments - Collaborations and License Agreements (Details)

v3.22.1
Contingencies and commitments - Collaborations and License Agreements (Details) - USD ($)
 1 Months Ended 12 Months Ended
Jun. 30, 2019
Feb. 29, 2016
Nov. 30, 2015
Dec. 31, 2018
Dec. 31, 2017
Mar. 31, 2022
Collaboration and license agreement | Universal Cells, Inc.            
Collaboration and License Agreement            
Upfront license and start-up fees     $ 2,500,000      
Milestone payments   $ 3,000,000   $ 200,000 $ 900,000  
Collaboration and license agreement | Universal Cells, Inc. | Maximum            
Collaboration and License Agreement            
Potential milestone payments           $ 37,600,000
Milestone payments one accrued but not yet paid           800,000
Milestone payments two accrued but not yet paid           500,000
Milestone payments three accrued but not yet paid           2,000,000
Research and development | Collaboration agreement | Alpine Immune Sciences Inc.            
Collaboration and License Agreement            
Milestone payment accrued but not yet paid           $ 1,000,000
Upfront license fees $ 2,000,000          
Research and development | Collaboration agreement | Alpine Immune Sciences Inc. | Maximum            
Collaboration and License Agreement            
Potential milestone payments $ 288,000,000